Ladies and gentlemen, thank you for standing by, and welcome to the Motus GI Holdings, Inc.'s second quarter 2022 financial and operational update. At this time, all participants are in a listen-only mode. There will be a presentation by the Motus management team, followed by a question-and-answer session. I must advise you all that the conference today is being recorded. I'd like to turn the call over to Garth Russell of LifeSci Advisors. Please go ahead, sir. Thank you, operator, and thank you everyone for joining us for the Motus GI second quarter 2022 update call today. Representing the company are Tim Moran, Chief Executive Officer, Andrew Taylor, Chief Financial Officer, and Mark Pomeranz, President and Chief Operating Officer of Motus GI. Before turning the call over to management for their opening remarks, I would like to take a minute to remind you that this conference call and webcast will contain certain forward-looking statements about the company. These statements are subject to certain risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We will not undertake any obligation to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and our periodic reports on Form 10-Q and 8-K filed with the SEC. I would now like to turn the call over to Tim Moran, CEO of Motus GI. Tim, the floor is yours. Thanks, Garth, and good afternoon, everyone. Thank you for joining our call today. I'm pleased to share an update on our progress through the second quarter of 2022, as well as provide early insights to what we are seeing in the third quarter. Following my updates, Andrew will provide an overview of our financial performance for the second quarter, and then we will open the call to take your questions. Let's get started. On our last call, I outlined the important milestones achieved over the past two years, which resulted in broader market awareness of Pure-Vu, enhanced sales strategies, stronger key opinion leader relationships, and an initial foundation of established customers. We are proud of these accomplishments as they each played a role in getting us to an important inflection point in the second quarter. Our product offering, sales team, and business outlook have each emerged stronger than ever, and we are seeing the most open access to healthcare centers in recent years. The core driver behind this inflection point was receiving FDA approval of the Pure-Vu EVS system late in Q1 2022, closely followed by its commercial launch. In June, we completed the first full quarter with the new system, and I am proud to say that the team is delivering on our plan, most notably in achieving the highest quarterly revenues in the company's history. It's important to understand the fundamental drivers that delivered these results. First, we're effectively placing the Pure-Vu EVS in a growing number of hospitals, which was one of the commitments I outlined on our March call shortly after receiving approval of the Pure-Vu EVS system. I projected that we expected to have Pure-Vu EVS placed in approximately 12 sites in the near- term. I am pleased to report that through the end of the second quarter, we now have the system placed in approximately 18 U.S. hospitals. When analyzing this number, I think it's worth noting that these 18 sites are comprised of a healthy blend between prior and new users and the mix of academic, community, rural, and VA hospitals. We believe this reflects not only satisfaction by our previous Pure-Vu users, but also the expansion to new segments of the U.S. hospital system. The trajectory of our long-term growth will be determined by how many procedures are performed utilizing our system at an individual site on a consistent basis. Therefore, we believe it's equally or even more important that we are seeing positive initial indicators around utilization and not just system placements. Two key metrics we're tracking are procedures per month by facility and the number of physician users. I am pleased to report that each of these metrics are moving in the right direction and being driven by activity at both new and existing hospital customers. Let me expand on one of these metrics a bit further. Expanding our base of physician users is important as it speaks to our ability to extend adoption beyond the initial physician champion we worked with during the evaluation period. One example from Q2 at a large community hospital in Dallas, we had eight different physicians utilizing Pure-Vu across their first 10 procedures. Additionally, this included both fellows and residents, which we believe highlights the simplicity we've built into the Pure-Vu EVS system. Looking ahead, our pipeline continues to grow with multiple new account evaluations targeted in the third quarter. One aspect of our commercial strategy, which I've referenced in the past, is the land and expand approach or the targeting of hospitals within a health system following approval at the flagship center to use the Pure-Vu EVS. This plan is now taking shape as exemplified by the Memorial Hermann Health System, where last quarter, after success in the main hospital, we initiated an evaluation in one of their largest satellite facilities. We have spent much of the past two years networking with, educating, and training some of the top hospitals and physicians in the country, which we believe positions us well within many of their health systems to secure evaluations of the Pure-Vu EVS at network hospitals. While not a traditional hospital network, we have seen a strong interest within the Veterans Affairs medical centers with some compelling results in our initial evaluations. We believe the VA health system in the U.S., which consists of approximately 170 medical centers across the country, represents a high-yield opportunity for adoption of the Pure-Vu EVS system. We are finding that these VA medical centers have a large backlog of colonoscopies, and if they can't see the patient within 28 days, the VA must pay another private hospital for services rendered. They also have a large catchment area, meaning patients are often traveling long distances to get to their nearest facility. Hence, canceled colonoscopies are viewed very unfavorably. A good illustration of our procedural utilization tracking and the real potential at these accounts is that we recently engaged with a VA in the Midwest, and they subsequently performed more than 30 Pure-Vu procedures during the second quarter alone. We are actively conducting evaluations at additional VA medical centers across the U.S., which we expect will result in new commercial agreements in the third and fourth quarters. While I've been giving a lot of credit to the Pure-Vu EVS system itself to this point, I want to call attention to our growing sales team. As you can see, we have quickly taken advantage of these additional resources. It was just a couple of quarters ago that we expanded the team to gain the critical mass required to close opportunities in our pipeline, which is more important than ever as the administrative process in many of these hospitals is still slower than pre-COVID time frames. Each of the new salespeople come with a proven track record of selling GI products at many of the world's largest medical device companies. While certain members of the team are still ramping up, we believe they are all making a positive impact in cultivating the right accounts for driving Pure-Vu into the market. We now have 10 commercial resources strategically positioned across the U.S. As some of you might have heard me mention previously, one of the goals of this expansion was to have every major region covered. Now that we have this presence, we are reaching hospitals that have not had any previous interactions with our team in conducting evaluations. These early successes are quickly proving to us that scaling up is a key to our long-term success. Now let's discuss our progress on other key upcoming catalysts. Let me first review our clinical study activity and outpatient reimbursement strategy. In May, during Digestive Disease Week 2022, we presented positive top-line data from the European outpatient clinical study, which concluded that the Pure-Vu system provides adequate cleaning in patients with a history of poor bowel preparation. The data shows that the Pure-Vu system improved the adequate cleansing rate from 31.8% to 97.7%. In addition, the study found that the Pure-Vu system may prevent repeat colonoscopies and clinical admissions for intensified bowel preparation. As a reminder, this study evaluated the clinical outcomes in patients with a history of poor bowel preparation using a low-volume prep and limited diet restrictions with the Pure-Vu system. We believe this data may be beneficial in our pursuit of outpatient reimbursement. Turning to our plans for penetrating the large outpatient screening market, there are 18 million outpatient procedures conducted in the U.S. each year, and currently, nearly one in four, or approximately 4.7 million of these patients, struggle to get a high-quality prep prior to their procedure. This can lead to delayed, aborted, and repeat procedures, which puts a burden on the healthcare system and the patient, both from a clinical and economic perspective. A critical step in our process to enter this market is generating key clinical and economic data via a large multi-center outpatient clinical trial. Based on learnings from the EU study and in working closely with a group of world-class key opinion leaders, we've been diligently developing a detailed protocol for this study. I am pleased to announce today that the study is based on a consecutive series design that we believe will generate real-world data using a tandem colonoscopy approach for patients that have poor visualization following a standard of care colonoscopy. The study will look at approximately 1,000 patients using an adaptive statistical plan with the primary endpoint designed to show a significant reduction in the number of aborted or poor quality exams that lead to an early repeat procedure as defined by the Gastroenterology Tri-Society guidelines. According to the literature, early repeat exams happen between 10% and 20% of the time in outpatient colonoscopies, and many patients don't come back as prescribed, which leaves them at a higher risk for an interval cancer, especially for patients at high risk for CRC. The study will be performed at a mix of academic and community hospitals, as well as ambulatory surgery centers. We expect to initiate the study before the end of this year, and we'll keep you apprised of our progress. In terms of ongoing product innovation, as I have discussed on previous calls, we have initiated a project to add upper GI capabilities to the new Pure-Vu EVS platform, which we're calling the Pure-Vu EVS Gastro device. We believe this device is on track to launch into the U.S. market in the first half of 2023. The Pure-Vu EVS Gastro will leverage the existing workstation infrastructure, which we believe may accelerate its penetration into the market. Some of the key enhancements in the EVS system, such as a much larger suction channel, more efficient irrigation jets, a smaller profile, and improved flexibility, will be further optimized to allow the system to provide broad utility in an upper GI procedure. I'm pleased to report that preclinical tests support these benefits, as well as the system's ability to help rapidly clear debris from the upper GI tract. In addition, KOL feedback has been very positive on the latest prototype devices. Finally, turning to potential strategic partnerships and collaborations. We continue to pursue various opportunities with strategic partners. Now that we've launched the Pure-Vu EVS into the market and the product performance has been strong, we believe these opportunities may become actionable. Our focus in evaluating these opportunities is centered upon accelerating our commercial progress and potentially strengthening our balance sheet. With that, I will now turn the call over to Andrew to provide detail on our Q2 2022 financials. Thank you, Tim, and thank you everyone for joining us today. We reported revenue for the second quarter 2022 of $185,000 compared to $100,000 for the same period last year, and $20,000 in the first quarter 2022. Revenues for the second quarter were primarily derived from disposable sleeve sales and were made up of a mix between reorders from existing sites and new customer orders. For the three months ended June 30, 2022, we reported a net loss attributable to common shareholders of approximately $5.1 million or $1.86 per basic and diluted share, compared to a net loss attributable to common shareholders of $4.7 million or $1.99 per basic and diluted share for the same period last year. Please note that this per share data is on a split-adjusted basis resulting from our reverse stock split effective as of July 25th, 2022. During the second quarter 2022, net cash used in operating activities and for the purchase of fixed assets was $4.6 million compared to $3.2 million for the same period of 2021. At June 30, 2022, we reported $15.8 million in cash and cash equivalents, which includes our fully funded credit facility with Kreos Capital. There are no financial or liquidity covenants associated with this facility. Our current cash balance allows us to continue executing on our near-term catalysts and is expected to meet our overall anticipated cash needs into the first quarter of 2023. With that, I'll now turn the call back over to Tim. Thanks, Andrew, and thank you everyone for joining our call today. We are encouraged by our progress in the first full quarter since the commercial launch of the Pure-Vu EVS system and are working to drive utilization at existing sites while also opening new accounts. We believe executing on both fronts will help to drive consistent long-term sequential revenue growth. After just a few months in the market, we have more hospitals using Pure-Vu EVS than our previous Gen2 system, and we continue to work through our pipeline of opportunities. In addition, we remain focused on initiating our large multi-center clinical study in Q4, which we believe could play a key role in the eventual pursuit of reimbursement in the large outpatient market. I'll now ask the operator to open the call for your questions. Thank you very much, sir. At this time, we will be conducting our question -and- answer session. If you would like to ask a question, please press star -one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star -two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. We have our first question from the line of Steven Lichtman with Oppenheimer. Please go ahead. Thank you. Hi, guys. Hey, Steve. I was wondering if we could start with just a few metrics here in the early days of EVS launch. Can you update us on number of active evaluations you have and the number of target hospitals in the pipeline. Also Tim, you gave us one example from the VA in terms of utilization, but I'm wondering if you could broaden that out and give, you know, any other commentary you can give us in terms of what utilization is starting to look like on a monthly basis for your initial customers here. Sure, Steve. Thanks for the question. I appreciate it. Let me start kind of at the macro level. We are still managing a pipeline of, call it about 100 accounts. The way to think about that is each rep has typically a minimum of about 10 sites that they keep cultivated. We've talked about this before, but they go through a qualification process to ensure that they're a good target for our system, and then as they move into evaluation and ultimately a close, they're backfilling into that pipeline. That's kind of the number that we're managing from at a macro level. As you heard me mention in the prepared remarks, we have 18 sites now that have the system in place. We have, I would tell you, double-digit evaluations, both started and will be started here in the third quarter. Each rep is working towards getting a couple of evaluations going. I'm really pleased with their progress. You know, a lot of it speaks to the simplicity of the training now that's involved with our new device, with the EVS system. We've talked a lot about this in the past, and one of the reasons we invested in this iteration was to make it simpler for the staff to be able to load this device and get it ready for the physician to utilize, thereby allowing our reps to move on and be at other sites. Open new accounts and not spend, you know, week after week, you know, training folks on getting the device utilized. Really pleased with how that's cultivated, you know, a really nice pipeline to work from. You see in our first quarter, it translated into, you know, a nice uptick in revenue. We're expecting that to continue and hopefully accelerate even from where we were in Q2. In terms of utilization, Steve, you know, that's the other part of this with the new device. We've made the navigation simpler. We're now getting the product into the hands of more physicians, not just the advanced endoscopists, but the general GI physicians. In some cases, even fellows and residents have done procedures, which is allowing us to drive more utilization. One, expansion of the number of physicians and the types of physicians that can utilize it. Then two, because we updated our EVS system with the removal of the reusable loading fixture that we talked about in the past, we're now able to use this device for rescue procedures. That's enabling new procedures that we weren't getting in the past. If you kind of hearken back to the original analysis that we had done when we first came out into the market with Gen2, we said we were looking for somewhere between, call it 15-20 procedures per quarter as an initial baseline. We're seeing that tick up. You know, I gave an example of just one site that did double that in Q2. We have others that are also outpacing that number. As we get another quarter or so under our belt, Steve, I'll give you harder metrics. I think we want to have, you know, let's say two or so quarters under and see a real trend. But we're already outpacing our initial estimates that we had with Gen2. That's helpful. Thanks, Tim. On the outpatient side, have you guys had any initial discussions with payers, and is that giving you confidence in terms of the design of this study, that you know if positive that would be adequate to garner reimbursement? Sure. Let me start on that, and then I'll ask Mark to add some additional detail. I want to just remind everyone that earlier this year, we brought in additional talent in our clinical group, a vice president of clinical affairs that came from one of the largest medical device companies over to Motus GI. She's working closely with Mark, and they've engaged a really high-powered group of leading gastroenterologists from around the country to help with the design of the study. Also through their relationships with payers, including the government and CMS, we have had engagement, and that's been really important as we've put together this design. Mark can speak a little bit in a little bit more detail, Steve, about the design and why we chose that. I'm really pleased with the work and the progress that our clinical team has done here to get us prepared to initiate this study. Mark, let me kick it over to you for a little bit more color. Great. Thanks, Tim. Yeah, as Tim outlined, Steve, you know, we've had an ongoing dialogue with CMS. We've had some formal meetings, and we keep them abreast of everything going on. As Tim said, you know, some of the folks that are advising us are the people that have written the guidelines for the Tri-Society, GI society. That's incredibly helpful. You know, we've made sure we keep in the key tenets that, you know, CMS and, you know, frankly, other payers want. You know, it's making sure first and foremost we are able to capture the size of the problem. Next, making sure with the spread of sites that we will use, that we make sure the data we collect is generalizable. We really can show a substantial clinical improvement as well. We've kind of considered all those things in the study. You know, that's the nice thing with, you know, making it a real-world consecutive design is, you know, as patients aren't successful with the standard of care, we can show the ability to convert that to a successful high-quality exam with Pure-Vu. You know, looking at not only avoiding that repeat procedure, but ideally getting, you know, secondary endpoints around, you know, detection rates and other things as well. Great. Thanks, Mark. Maybe lastly for me with coming off of the positive EU study, is this data that can be used for a CE mark submission? If it is, will you move forward with that, or will that really be predicated on first establishing a partnership? Yeah. Mark, why don't you take the first part, and then I'll add a bit after. Yep. Sure. Steve, we're actually already active in the engagement with our notified body and moving forward, you know, with the whole EU MDR process. That is going as well as we can expect. That's going well on that. We're already in that arena with, you know, moving forward to get a CE mark for EVS. As you probably know, you know, the timelines on that with, you know, what's going on in the European Union are quite long, but we're in the queue with that process. Steve, I'll just add, as we set out in this year, there were a couple key priorities for the company. Obviously, commercialization being first and foremost, this outpatient opportunity and preparing ourselves for reimbursement. The third being, preparing ourselves for eventual entry into other OUS markets. As you mentioned, CE mark's critical. We brought in a very talented quality leader that has been spearheading this MDR process, and it's quite complex as I'm sure you know from speaking with other companies. The team's done a great job to position us to get through this process and then be prepared to get the CE mark. We'll update you when we have closer timelines. As Mark said, that's it's headed down that path already. Great. Thank you, guys. Thanks, Steve. Thank you. We have next question from the line of Ben Haynor with Alliance Global Partners. Please go ahead. Good afternoon, gentlemen. Thanks for taking the questions and congrats on the progress. First for me, you mentioned the 18 hospitals that you've gotten approved in by the end of Q2, that there's a nice mix there and you know, definitely appreciate the color that you gave on the VA situation. I was wondering if you could provide any color on you know, kind of the other mix of accounts, you know, the teaching hospitals, community hospitals, rural hospitals that you mentioned. You know, is there anything surprising then that you've run across there, you know, either positively or negatively? Yeah. Thank you, Ben, for the question. Listen, I think the fact that we're now branching out well beyond just academic medical centers, right? Which is where we spent the majority of our time over the last two years, which you know makes sense when you come with a new technology, you want to get in front of the KOLs, you know, and get them up you know on the podium talking about your technology and supporting you. Now that we've got a larger sales team in more areas, and we've got a device that is simpler to use, it's allowing us to kind of spread our wings to these other locations. I would tell you that, as I mentioned in the prepared remarks, and you heard the VA while it's not surprising, I think we're very encouraged by their feedback. It's not just one site, it's multiple sites, and we also have several that are going to go into evaluation here in the third quarter. You know, what's unique about that is their patient population, oftentimes due to medical condition, you know, comorbidities or even, you know, injuries, right? Have a dificult time prepping. They're perfect for the Pure-Vu system, but they're also traveling from long distances, as I mentioned earlier, right? It just puts so much more emphasis on ensuring that they get their procedure done the first time, and that's truly what Pure-Vu has been designed to do. But we've been able to kinda translate that learning into other rural facilities that still are, you know, maybe large regional trauma centers, but they're in more remote locations, based on the VA learnings to say, "Hey, how many patients are traveling to get here from, you know, an hour away or so? And what happens when that patient doesn't get their exam done on time? What's the implication to the patient? What's the implication to the cost of the facility?" And that's really resonating. You know, I would say those are a couple of the learnings now that we've branched out beyond just the academic medical centers. Okay. That's helpful. Thanks for the color there. You know, just kind of in a situation where the VA isn't able to get the colonoscopy done within, I think you said 28 days, they need to pay another hospital to do it. You know, what's typical when they're paying another hospital to do it? I mean, does the hospital look at the VA and say, "You know, that's kinda government paying for it, let's tattoo them on the bill," or how does that work? You know, Ben, I probably couldn't get into the specific nuances of exactly how that, you know, billing is coordinated. What we've heard from our VAs, you know, is that, "Hey, we're under pressure because, one, we have a backlog from, you know, what's occurred here with the pandemic. But two, if we can't see these patients, you know, we're not going to withhold care for them." You know, there's a process in place whereby then that, you know, that veteran would be able to go to a local facility that isn't run by the government. You know, at that point, the government is reimbursing them. In terms of costs and, you know, what they're charging, I don't have that, those specific details, but I know it's been a hot button, and been something that's motivated these physicians when we've come to talk to them about the Pure-Vu solution to say, "Hey, we've got something that will allow you to ensure that these are getting done on time." That, that's been really positive. Okay, fair enough. Then, you know, you mentioned on the Pure-Vu EVS upper GI offering and, you know, you've done the preclinical work and the KOL feedback has been good. You know, really, how much more development needs to take place there to get that out in the first half of 2023? Yeah. I think we're pretty far along, Ben. There's two things. You know, we have very high hopes for what this upper GI addition can do to the portfolio, right? We've talked about this, you know, several times in the past. It's a, you know, a high risk procedure. The mortality rates are higher, and we've talked to a lot of physicians that are, you know, yearning for something in this space that will allow them visualization when they're dealing with blood and blood clots and stomach contents, right? We want to get it right. That being said, you know, I think from a development perspective, a lot of what went into the improvements of EVS are going to play very well in this space. We are going to do another animal lab. We have already scheduled for early part of this fall. I think, you know, in the timeline that we've given in terms of first half of 2023, we also are always conservative in what the regulatory approval process could look like. We've been very fortunate. As you know, we've had our special 510(k)s approved in, you know, record time twice now. We don't want to build that into our timeline and miss the expectation. Just know that we're pushing to accelerate that launch as early in 2023 as possible. Okay. That's helpful because my follow-up was going to be, you know, why should investors believe you when, you know, on the timeline when your most recent approvals have come so quickly? Yeah. Yeah. I mean, we have to consider, you know, that it could take upwards of 90 days. But in all likelihood, if we follow a similar path, we can shorten that timeline. Okay. Great. Well, that's all I had, gentlemen. Congrats on the progress, and thanks for taking the questions. Thank you, Ben. Thank you. We have next question from the line of Swayampakula Ramakanth with H.C. Wainwright. Please go ahead. Hi. Thanks for taking my questions. Upon Ben's question with respect to EVS Gastro, you mentioned that the KOL feedback has been positive. Maybe you can expand a little bit on that. What is that they really liked about the EVS Gastro? Is it the enhancements? Can you provide additional color on that? Sure. There's a couple things that we learned with our Gen2 approval in that space. One, suction and having a large suction port is very critical because in that procedure, Swayampakula Ramakanth, at times you can be dealing with very large blood clots that are adherent and can be very difficult to get out of the patient. What oftentimes a physician will do is they're going to work through the working channel of their gastroscope to break that clot up into smaller pieces. They can use the, you know, instruments to go down the working channel, break that clot up into smaller pieces, and then suction those pieces out. The feedback was, hey, the larger the suction channel you can provide, the better. What's also nice about our device is they're getting the suction without interrupting that working channel, right? They can be doing the work, breaking up the clot while simultaneously suctioning. Incorporating a larger suction channel was one bit of feedback that's important for that procedure. The other was most often, when you're passing the gastroscope with the Pure-Vu sleeve, you're doing that on an intubated patient, so they have an intubation tube as well. The material of the tip of our disposable sleeve in the second generation was more of a hard plastic material. There was feedback to say, "Hey, could you change that material to be a bit more malleable, therefore reducing any risk of, you know, causing any irritation to the esophagus?" That's something that we've incorporated into the EVS version. Those are two big areas of things that have been incorporated into the system that we think are going to play very well in upper GI. You know, let me ask Mark if he wants to add any other points I might have missed, you know, in feedback that we got from our first animal study or anything else in that regard. Mark, I'll turn to you. Great. Thanks. Thanks, Tim. I think you hit the key aspects. You know, the other things we're looking at, you know, is also increasing the energy in our irrigation jets because the lining of the stomach is much stronger than the colon, so we can actually put more energy into the irrigation to help with breaking up the clots, as Tim talked about. Just the overall flexibility of the entire system is dramatically improved. That, you know, helps navigate the upper esophageal valve, which can be difficult, especially in compromised patients. Thanks for the detailed color. With respect to macro headwinds, the macro headwinds has been pretty harsh during second quarter, but it looks like you had a really great quarter. Still, I'd like to ask this question. Just curious, you know, whether the environment that you saw in the second quarter, it kinda triggered any new shift that you have never seen previously, maybe like are customers leaning more towards lease versus capital purchase? Is there any other new trend that you saw that you can talk about? Yeah, thank you for that. You know, it's interesting. Listen, we're pleased with this first quarter of launch. Like you said, we had a good quarter. You know what? This I truly believe is just the start for us. What I will say is you brought up capital. You know, capital, as you've heard us talk about, you've heard other companies that have been reporting, the capital environment continues to be constrained. I think we've done a good job with offering variety to our customers to ensure that we get the device utilized. At the end of the day, driving conviction around the procedure and the repeat business that comes from these disposables is really what it's all about when you kind of project the growth over the next three to five years for the company. But that being said, you know, capital is part of the process. You know, we're seeing folks look at our lease programs, our simple rental programs. As you know, we've always had a kind of a bundled agreement or a tiered pricing agreement where you can pay a little bit more for the sleeves but get the capital at no charge. I think that's helping us get these accounts up and running. But I'm also confident that we will start to see some capital come through here in the third quarter. It'll continue to be a difficult environment, I think, for the remainder of this year. All right. That's it from me. Thanks. Great. Thanks. Thank you, sir. Ladies and gentlemen, we have reached the end of the question and answer session, and I'd like to hand the call back over to Tim Moran, CEO, for closing remarks. Over to you, sir. Great. Thank you. I just want to thank everyone for joining our call today. We're encouraged, as I said, getting this new product launched out in the market, having a larger sales team, as you can see, is driving results. You know, the company remains extremely focused on one execution. Executing on our commercial plan, driving utilization and opening new accounts. That is, as I said earlier, first and foremost, our single largest priority. You heard today we're making great progress in this upcoming catalyst of the large multi-center trial investment, which we believe has the potential to open up reimbursement in a very, very large outpatient market. That's something that I think will be important to the company, to our investors and shareholder value in the future. Finally, you know, we're adding key talent where necessary to take advantage and capitalize on all of these opportunities that we have as a company. Thanks for joining our call today. We'll look forward to updating everyone on our progress in our next earnings call for Q3. Thank you very much, sir. Ladies and gentlemen, this concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.